Following the failure of two of Vifor’s partnered assetsnin just over a year, the group needed to plug the gaps in its pipeline.nIt has opted to do so via two buyouts of companies looking at chronic nkidney disease, complimenting Vifor’s tight focus. The Spanish group nSanifit has been taken out for €205m ($231m), with potential milestones nof up to €170m and tiered royalties. Vifor will get full global rights nto Sanifit’s thrice-weekly intravenous project SNF472, which it calls a nfirst-in-class inhibitor of vascular calcification. The asset is nintended for the treatment of calcific uremic arteriolopathy (CUA) and nperipheral artery disease (PAD) in patients with end-stage renal ndisease, and results from an ongoing phase 3 CUA study could come next nyear.
The poster child of the Spanish biotech scene has secured its exit. Having twice smashed the Spanish biotech financing record in recent years, Sanifit has now accepted a 205 million euro ($231 million) buyout bid from Vifor Pharma.
Palma, Spain and San Diego, USA, February 10, 2021 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead compound SNF472 for the treatment of peripheral arterial disease (PAD) in patients with end-stage kidney disease (ESKD).
Palma, Spain and San Diego, USA, October 22, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, today announced the presentation of new data on lead candidate SNF472 today at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting.
Palma, Spain and San Diego, USA, 20 July 2020 – Sanifit, a clinical-stage biopharmaceutical company developing treatments for calcification disorders, announces today that it will start a new clinical development program to investigate the effect of SNF472 in End Stage Kidney Disease (ESKD) patients with Peripheral Artery Disease (PAD), a cardiovascular disease affecting peripheral arteries by reducing blood flow to the limbs.
Palma, Spain and San Diego, USA, 25 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that data examining the mechanism of action of SNF472, Sanifit’s lead compound in development, has been published in the British Journal of Pharmacology (BJP).
Palma, Spain and San Diego, USA, 13 February 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that the first patient has successfully been dosed in its pivotal phase 3 trial of the Company’s lead asset SNF472, for the treatment of the orphan disease calciphylaxis or calcific uremic arteriolopathy (“CUA”).